Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E HUGHES

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Nature Chemistry|March 2, 2023
Alkyl sulfinates as cross-coupling partners for programmable and stereospecific installation of C(sp<sup>3</sup>) bioisosteresMin Zhou, Jet Tsien, Ryan Dykstra, et al.
Scientific Reports|July 18, 2019
Publisher Correction: Tidal and diel orchestration of behaviour and gene expression in an intertidal molluscY Schnytzer, N Simon-Blecher, J Li, et al.
Scientific Reports|March 22, 2018
Tidal and diel orchestration of behaviour and gene expression in an intertidal molluscY Schnytzer, N Simon-Blecher, J Li, et al.
The Journal of Organic Chemistry|January 10, 2024
Nickel-Catalyzed Reductive Arylation of Redox Active Esters for the Synthesis of α-Aryl Nitriles: Investigation of a Chlorosilane AdditiveNicholas W M Michel, Alexis L Gabbey, Racquel K Edjoc, et al.
Human Genetics|March 1, 1996
Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitusA I Blakemore, A Cox, A M Gonzalez, et al.
Nature Chemistry|October 26, 2023
Programmable late-stage functionalization of bridge-substituted bicyclo[1.1.1]pentane bis-boronatesYangyang Yang, Jet Tsien, Ryan Dykstra, et al.
Breast Cancer Research and Treatment|August 3, 2011
The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centersA M Brewster, C Etzel, R Zhou, et al.
Journal of Pharmaceutical Sciences|December 7, 2024
Attribute ranging as a coordinated strategy between drug substance and drug product to accelerate commercial process nominationClara Hartmanshenn, Alexander Bechtold, Thomas Kwok, et al.
ESMO Open|June 4, 2025
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclibC Corti, A R Martin, P T Kurnia, et al.
ESMO Open|January 18, 2025
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2X Qiu, P Tarantino, R Li, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Nature Chemistry|March 2, 2023
Alkyl sulfinates as cross-coupling partners for programmable and stereospecific installation of C(sp<sup>3</sup>) bioisosteresMin Zhou, Jet Tsien, Ryan Dykstra, et al.
Scientific Reports|July 18, 2019
Publisher Correction: Tidal and diel orchestration of behaviour and gene expression in an intertidal molluscY Schnytzer, N Simon-Blecher, J Li, et al.
Scientific Reports|March 22, 2018
Tidal and diel orchestration of behaviour and gene expression in an intertidal molluscY Schnytzer, N Simon-Blecher, J Li, et al.
The Journal of Organic Chemistry|January 10, 2024
Nickel-Catalyzed Reductive Arylation of Redox Active Esters for the Synthesis of α-Aryl Nitriles: Investigation of a Chlorosilane AdditiveNicholas W M Michel, Alexis L Gabbey, Racquel K Edjoc, et al.
Human Genetics|March 1, 1996
Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitusA I Blakemore, A Cox, A M Gonzalez, et al.
Nature Chemistry|October 26, 2023
Programmable late-stage functionalization of bridge-substituted bicyclo[1.1.1]pentane bis-boronatesYangyang Yang, Jet Tsien, Ryan Dykstra, et al.
Breast Cancer Research and Treatment|August 3, 2011
The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centersA M Brewster, C Etzel, R Zhou, et al.
Journal of Pharmaceutical Sciences|December 7, 2024
Attribute ranging as a coordinated strategy between drug substance and drug product to accelerate commercial process nominationClara Hartmanshenn, Alexander Bechtold, Thomas Kwok, et al.
ESMO Open|June 4, 2025
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclibC Corti, A R Martin, P T Kurnia, et al.
ESMO Open|January 18, 2025
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2X Qiu, P Tarantino, R Li, et al.
Pageof 7